May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Mutation Spectrum of Usher Syndrome in Finland
Author Affiliations & Notes
  • H. Vastinsalo
    Medical Genetics, Folkhalsan Institute of Genetics, Helsinki, Finland
  • J. Isosomppi
    Medical Genetics, Folkhalsan Institute of Genetics, Helsinki, Finland
  • L. Kleemola
    Department of Otorhinolaryngology, Tampere University Hospital, Tampere, Finland
  • L. Jauhola
    Department of Ophthalmology, Paijat-Hame Central Hospital, Lahti, Finland
  • E.-M. Sankila
    Helsinki University Eye Hospital, Helsinki, Finland
  • Footnotes
    Commercial Relationships  H. Vastinsalo, None; J. Isosomppi, None; L. Kleemola, None; L. Jauhola, None; E. Sankila, None.
  • Footnotes
    Support  The Eye and Tissue Bank Foundation (Finland), De Blindas Vänner Foundation
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2121. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Vastinsalo, J. Isosomppi, L. Kleemola, L. Jauhola, E.-M. Sankila; Mutation Spectrum of Usher Syndrome in Finland. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2121.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The epidemiological studies of Usher syndrome (USH) in Finland suggested that the distribution of clinical USH types is 40% USH3, 34% USH1, and 12 % USH2 (14% unknown). We previously detected a USH3A (CLRN1) founder mutation in most patients who were clinically diagnosed with USH3. Due to the considerable overlap of clinical symptoms between the USH types, however, some patients clinically characterized as USH3 did not show CLRN1 mutations. In contrast to USH3A, USH1 is heterogenic in Finland. Recently we detected three novel USH1B mutations in two unrelated Finnish USH1 patients. The purpose of this study was to further investigate the USH mutation spectrum in Finnish patients without previously known USH mutations.

Methods: : For this study, we analyzed samples from 14 USH patients without previously known mutations using the Asper Genetics USH mutation chip.

Results: : From these 14 Finnish USH patients we detected seven different polymorphisms/mutations in heterozygous form: two in MYO7A, and five in USH2A genes. These variations were not previously known to exist in the Finnish population.

Conclusions: : Mutation chips are useful in detecting mutations in a heterogeneous disease such as USH. Based on our study, there is considerable heterogeneity of USH1 and USH2 in Finland, in contrast to USH3 which is merely caused by a founder mutation. All seven mutations detected in 14 USH patients were in heterozygous from. We are presently sequencing coding regions of MYO7A and USH2A genes of these patients in order to detect the second mutations.

Keywords: genetics • retinal degenerations: hereditary • mutations 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.